Tanshinone IIA Has a Potential Therapeutic Effect on Kawasaki Disease and Suppresses Megakaryocytes in Rabbits With Immune Vasculitis.
Kawasaki disease
apoptosis
immune vasculitis
megakaryocyte
tanshinone IIA
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
02
2022
accepted:
22
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
It is urgent to find out an alternative therapy for Kawasaki disease (KD) since around 20% patients are resistant to intravenous immunoglobulin (IVIG) or aspirin. Tanshinone IIA is the active component of the traditional Chinese medicine Danshen ( Kawasaki disease patients were recruited and prescribed with tanshinone IIA in the absence or presence of aspirin and IVIG, and the inflammatory responses and platelet functions were determined. Megakaryocytes (MKs) isolated from rabbits with immune vasculitis and human megakaryocytic CHRF-288-11 cells were treated with tanshinone IIA to examine the colony forming unit (CFU) and apoptosis, respectively. Microarray assay was conducted to identify potential targets of tanshinone IIA-induced apoptosis. Tanshinone IIA reduced the serum levels of C-reactive protein (CRP), interleukin (IL)-1β, IL-6, and P-selectin in KD patients; such inhibitory effect was more significant compared to aspirin and IVIG. It also dose-dependently lowered the levels of tumor necrosis factor (TNF)-α and IL-8 in peripheral blood mononuclear cells isolated from KD patients. In rabbits with immune vasculitis, tanshinone IIA significantly reduced the serum levels of proinflammatory cytokines and platelet functions. In addition, tanshinone IIA significantly decreased the number of bone marrow MKs and inhibited the Colony Forming Unit-Megakaryocyte (CFU-MK) formation. In human megakaryocytic CHRF-288-11 cells, tanshinone IIA induced caspase-dependent apoptosis, probably through up-regulating TNF receptor superfamily member 9 (TNFRSF9) and the receptor (TNFRSF)-interacting serine/threonine-protein kinase 1 (RIPK1), which may contribute to its anti-platelet and anti-inflammatory properties. Tanshinone IIA exerts better anti-inflammatory and anti-platelet effects in treating KD patients than aspirin and IVIG. It attenuates immune vasculitis likely by inhibiting IL-mediated megakaryopoiesis and inducing TNFRSF9/RIPK1/caspase-dependent megakaryocytic apoptosis. The findings therefore suggest that tanshinone IIA may be a promising alternative therapy for the treatment of KD.
Sections du résumé
Background and Objective
UNASSIGNED
It is urgent to find out an alternative therapy for Kawasaki disease (KD) since around 20% patients are resistant to intravenous immunoglobulin (IVIG) or aspirin. Tanshinone IIA is the active component of the traditional Chinese medicine Danshen (
Methods
UNASSIGNED
Kawasaki disease patients were recruited and prescribed with tanshinone IIA in the absence or presence of aspirin and IVIG, and the inflammatory responses and platelet functions were determined. Megakaryocytes (MKs) isolated from rabbits with immune vasculitis and human megakaryocytic CHRF-288-11 cells were treated with tanshinone IIA to examine the colony forming unit (CFU) and apoptosis, respectively. Microarray assay was conducted to identify potential targets of tanshinone IIA-induced apoptosis.
Results
UNASSIGNED
Tanshinone IIA reduced the serum levels of C-reactive protein (CRP), interleukin (IL)-1β, IL-6, and P-selectin in KD patients; such inhibitory effect was more significant compared to aspirin and IVIG. It also dose-dependently lowered the levels of tumor necrosis factor (TNF)-α and IL-8 in peripheral blood mononuclear cells isolated from KD patients. In rabbits with immune vasculitis, tanshinone IIA significantly reduced the serum levels of proinflammatory cytokines and platelet functions. In addition, tanshinone IIA significantly decreased the number of bone marrow MKs and inhibited the Colony Forming Unit-Megakaryocyte (CFU-MK) formation. In human megakaryocytic CHRF-288-11 cells, tanshinone IIA induced caspase-dependent apoptosis, probably through up-regulating TNF receptor superfamily member 9 (TNFRSF9) and the receptor (TNFRSF)-interacting serine/threonine-protein kinase 1 (RIPK1), which may contribute to its anti-platelet and anti-inflammatory properties.
Conclusion
UNASSIGNED
Tanshinone IIA exerts better anti-inflammatory and anti-platelet effects in treating KD patients than aspirin and IVIG. It attenuates immune vasculitis likely by inhibiting IL-mediated megakaryopoiesis and inducing TNFRSF9/RIPK1/caspase-dependent megakaryocytic apoptosis. The findings therefore suggest that tanshinone IIA may be a promising alternative therapy for the treatment of KD.
Identifiants
pubmed: 35498027
doi: 10.3389/fcvm.2022.873851
pmc: PMC9043496
doi:
Types de publication
Journal Article
Langues
eng
Pagination
873851Informations de copyright
Copyright © 2022 Chen, Shu, Su, Li, Zhang, Li, Lin, Yi, Zhan, Chen, Li, Yang, Zhou and Yang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Pharmacol. 2019 Jul 05;10:753
pubmed: 31338034
BMC Complement Altern Med. 2012 Jan 16;12:5
pubmed: 22248096
Eur J Med Res. 2020 Mar 17;25(1):8
pubmed: 32183905
Br J Haematol. 2000 Oct;111(1):371-80
pubmed: 11091227
Pediatr Rheumatol Online J. 2021 Mar 12;19(1):25
pubmed: 33712020
Nature. 2011 Mar 17;471(7338):373-6
pubmed: 21368761
Trends Immunol. 2014 Jan;35(1):32-7
pubmed: 24210164
Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):552-64
pubmed: 24458711
Eur J Pediatr. 2018 Aug;177(8):1279-1292
pubmed: 29948255
Biomed Pharmacother. 2019 Oct;118:109362
pubmed: 31545252
Pharmacol Res. 2021 Feb;164:105364
pubmed: 33285229
Cancer Lett. 2017 Sep 10;403:86-97
pubmed: 28602978
Circ Res. 2016 Apr 29;118(9):1392-408
pubmed: 27126649
J Infect. 2016 Jul 5;72 Suppl:S1-5
pubmed: 27241708
Mediators Inflamm. 2020 Jun 06;2020:4321912
pubmed: 32587470
Pediatr Res. 2005 Oct;58(4):784-90
pubmed: 16189210
Stem Cells. 2007 Jul;25(7):1800-6
pubmed: 17446559
J Pediatr. 2018 Dec;203:408-415.e3
pubmed: 30268398
Cell. 2008 May 16;133(4):693-703
pubmed: 18485876
Br J Pharmacol. 2014 Oct;171(19):4504-19
pubmed: 24902855
Antioxidants (Basel). 2021 Jun 23;10(7):
pubmed: 34201701
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
Nat Rev Rheumatol. 2020 Jul;16(7):391-405
pubmed: 32457494
Pharmacol Res. 2018 Mar;129:482-490
pubmed: 29158049
Int Immunopharmacol. 2014 Sep;22(1):277-84
pubmed: 25034709
Ultrastruct Pathol. 2013 Apr;37(2):139-45
pubmed: 23573894
Blood. 1995 Apr 1;85(7):1719-26
pubmed: 7535585
Trends Cardiovasc Med. 2016 May;26(4):297-303
pubmed: 26877187
J Neuroinflammation. 2012 Jul 16;9:173
pubmed: 22799524
Ann Transl Med. 2020 Oct;8(20):1295
pubmed: 33209875
Nat Rev Mol Cell Biol. 2020 Feb;21(2):85-100
pubmed: 31636403
Front Pediatr. 2020 Aug 25;8:493
pubmed: 32984207
Curr Med Chem. 2010;17(26):2897-905
pubmed: 20858171
Circ J. 2015;79(6):1349-56
pubmed: 25787672
Genes Dis. 2019 Sep 12;7(1):62-66
pubmed: 32181276
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1288-1300
pubmed: 31043076
Crit Care Med. 2010 Feb;38(2 Suppl):S26-34
pubmed: 20083910
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
Angiology. 1995 Aug;46(8):679-87
pubmed: 7639414
Blood. 2016 Mar 10;127(10):1249-59
pubmed: 26787733
Biomaterials. 2013 Sep;34(28):6893-905
pubmed: 23768781